FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983875560> ?p ?o ?g. }

• W2983875560 endingPage "40" @default.
• W2983875560 startingPage "40" @default.
• W2983875560 abstract "<h3>Importance</h3> Anti–vascular endothelial growth factor (anti-VEGF) is a breakthrough treatment for wet age-related macular degeneration (wAMD), the most common cause of blindness in western countries. Anti-VEGF treatment prevents vision loss and has been shown to produce vision gains lasting as long as 5 years. Although this treatment is costly, the benefits associated with vision gains are large. <h3>Objective</h3> To estimate the economic value of benefits, costs for patients with wAMD, and societal value in the United States generated from vision improvement associated with anti-VEGF treatment. <h3>Design, Setting, and Participants</h3> This economic evaluation study used data from the published literature to simulate vision outcomes for a cohort of 168 820 patients with wAMD aged 65 years or older and to translate them into economic variables. Data were collected and analyzed from March 2018 to November 2018. <h3>Main Outcomes and Measures</h3> Main outcomes included patient benefits, costs, and societal value. Each outcome was estimated for a newly diagnosed cohort and the full population across 5 years, with a focus on year 3 as the primary outcome because data beyond that point may be less representative of the general population. Drug costs were the weighted mean across anti-VEGF therapies. Two current treatment scenarios were considered: less frequent injections (mean [SD], 8.2 [1.6] injections annually) and more frequent injections (mean [range], 10.5 [6.8-13.1] injections annually). The 2 treatment innovation scenarios, improved adherence and best case, had the same vision outcomes as the current treatment scenarios had but included more patients treated from higher initiation and lower discontinuation. <h3>Results</h3> The study population included 168 820 patients aged 65 years at the time of diagnosis with wAMD. The underlying clinical trials that were used to parameterize the model did not stratify visual acuity outcomes or treatment frequency by sex; therefore, the model parameters could not be stratified by sex. The current treatment scenario of less frequent injections generated $1.1 billion for the full population in year 1 and $5.1 billion in year 3, whereas the scenario of more frequent injections generated $1.6 billion (year 1) and $8.2 billion (year 3). Three-year benefits ranged from $7.3 billion to $11.4 billion in the improved adherence scenario and from $9.7 billion to $15.0 billion if 100% of the patients initiated anti-VEGF treatment and the discontinuation rates were 6% per year or equivalent to clinical trial discontinuation (best-case scenario). Societal value (patient benefits net of treatment cost) ranged from $0.9 billion to $3.0 billion across 3 years in the current treatment scenarios and from $0.9 billion to $4.3 billion in the treatment innovation scenarios. <h3>Conclusions and Relevance</h3> This study’s findings suggest that improved vision associated with anti-VEGF treatment may provide economic value to patients and society if the outcomes match published outcomes data used in these analyses; however, future innovations that increase treatment utilization may result in added economic benefit." @default.
• W2983875560 created "2019-11-22" @default.
• W2983875560 creator A5008042781 @default.
• W2983875560 creator A5011663361 @default.
• W2983875560 creator A5026181496 @default.
• W2983875560 creator A5052043502 @default.
• W2983875560 creator A5052140640 @default.
• W2983875560 creator A5070921176 @default.
• W2983875560 date "2020-01-01" @default.
• W2983875560 modified "2023-10-11" @default.
• W2983875560 title "Economic Value of Anti–Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States" @default.
• W2983875560 cites W1786285359 @default.
• W2983875560 cites W1993399691 @default.
• W2983875560 cites W1998551984 @default.
• W2983875560 cites W2006370082 @default.
• W2983875560 cites W2011187017 @default.
• W2983875560 cites W2011393181 @default.
• W2983875560 cites W2015457963 @default.
• W2983875560 cites W2030068078 @default.
• W2983875560 cites W2041610458 @default.
• W2983875560 cites W2057433307 @default.
• W2983875560 cites W2058056848 @default.
• W2983875560 cites W2060115605 @default.
• W2983875560 cites W2086585123 @default.
• W2983875560 cites W2092501667 @default.
• W2983875560 cites W2126288352 @default.
• W2983875560 cites W2134161293 @default.
• W2983875560 cites W2136381651 @default.
• W2983875560 cites W2156846669 @default.
• W2983875560 cites W2167802532 @default.
• W2983875560 cites W2268273540 @default.
• W2983875560 cites W2316418129 @default.
• W2983875560 cites W2343042175 @default.
• W2983875560 cites W2555189142 @default.
• W2983875560 cites W2579987799 @default.
• W2983875560 cites W2732585901 @default.
• W2983875560 cites W2753708825 @default.
• W2983875560 cites W2784031367 @default.
• W2983875560 cites W2804532233 @default.
• W2983875560 cites W2805449877 @default.
• W2983875560 cites W2807398685 @default.
• W2983875560 cites W4285698150 @default.
• W2983875560 doi "https://doi.org/10.1001/jamaophthalmol.2019.4557" @default.
• W2983875560 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6865322" @default.
• W2983875560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31725830" @default.
• W2983875560 hasPublicationYear "2020" @default.
• W2983875560 type Work @default.
• W2983875560 sameAs 2983875560 @default.
• W2983875560 citedByCount "25" @default.
• W2983875560 countsByYear W29838755602020 @default.
• W2983875560 countsByYear W29838755602021 @default.
• W2983875560 countsByYear W29838755602022 @default.
• W2983875560 countsByYear W29838755602023 @default.
• W2983875560 crossrefType "journal-article" @default.
• W2983875560 hasAuthorship W2983875560A5008042781 @default.
• W2983875560 hasAuthorship W2983875560A5011663361 @default.
• W2983875560 hasAuthorship W2983875560A5026181496 @default.
• W2983875560 hasAuthorship W2983875560A5052043502 @default.
• W2983875560 hasAuthorship W2983875560A5052140640 @default.
• W2983875560 hasAuthorship W2983875560A5070921176 @default.
• W2983875560 hasBestOaLocation W29838755601 @default.
• W2983875560 hasConcept C118487528 @default.
• W2983875560 hasConcept C126322002 @default.
• W2983875560 hasConcept C187212893 @default.
• W2983875560 hasConcept C201903717 @default.
• W2983875560 hasConcept C2776403814 @default.
• W2983875560 hasConcept C2908647359 @default.
• W2983875560 hasConcept C71924100 @default.
• W2983875560 hasConcept C72563966 @default.
• W2983875560 hasConcept C99454951 @default.
• W2983875560 hasConceptScore W2983875560C118487528 @default.
• W2983875560 hasConceptScore W2983875560C126322002 @default.
• W2983875560 hasConceptScore W2983875560C187212893 @default.
• W2983875560 hasConceptScore W2983875560C201903717 @default.
• W2983875560 hasConceptScore W2983875560C2776403814 @default.
• W2983875560 hasConceptScore W2983875560C2908647359 @default.
• W2983875560 hasConceptScore W2983875560C71924100 @default.
• W2983875560 hasConceptScore W2983875560C72563966 @default.
• W2983875560 hasConceptScore W2983875560C99454951 @default.
• W2983875560 hasIssue "1" @default.
• W2983875560 hasLocation W29838755601 @default.
• W2983875560 hasLocation W29838755602 @default.
• W2983875560 hasOpenAccess W2983875560 @default.
• W2983875560 hasPrimaryLocation W29838755601 @default.
• W2983875560 hasRelatedWork W143545196 @default.
• W2983875560 hasRelatedWork W1521584897 @default.
• W2983875560 hasRelatedWork W1980275360 @default.
• W2983875560 hasRelatedWork W1986887406 @default.
• W2983875560 hasRelatedWork W2109177854 @default.
• W2983875560 hasRelatedWork W2238496498 @default.
• W2983875560 hasRelatedWork W2323619192 @default.
• W2983875560 hasRelatedWork W2416848835 @default.
• W2983875560 hasRelatedWork W2792210947 @default.
• W2983875560 hasRelatedWork W2563600304 @default.
• W2983875560 hasVolume "138" @default.
• W2983875560 isParatext "false" @default.
• W2983875560 isRetracted "false" @default.
• W2983875560 magId "2983875560" @default.

• next